The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a strong risk factor for coronary artery disease and heart failure, particularly heart failure with preserved ejection fraction (HFpEF). The aim of the ongoing MUSCAT-HF (It stands for Prospective Comparison of Luseogliflozin and Alpha-glucosidase on the Management of Diabetic Patients with Chronic Heart Failure and Preserved Ejection Fraction) trial is to evaluate the efficacy of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus voglibose, an alpha-glucosidase inhibitor, using brain natriuretic peptide (BNP) as the index of therapeutic effect in T2DM patients with HFpEF.


METHODS AND ANALYSIS
A total of 190 patients with T2DM and HFpEF (ejection fraction >45%) who are drug-naïve or taking any anti-diabetic agents will be randomised (1:1) to receive luseogliflozin 2.5 mg one time per day or voglibose 0.2 mg three times per day. The patients will be stratified by age (<65 years, ≥65 years), baseline haemoglobin A1c (<8.0%, ≥8.0%), baseline BNP (<100 pg/mL, ≥100 pg/mL), baseline renal function (estimated glomerular filtration rate ≥60 mL/min/1.73 m2, <60 mL/min/1.73 m2), use of thiazolidine or not and presence or absence of atrial fibrillation and flutter at screening. After randomisation, participants will receive the study drug for 12 weeks in addition to their background therapy. The primary endpoint is the proportional change in baseline BNP after 12 weeks of treatment. The key secondary endpoints are the change from baseline in the ratio of early mitral inflow velocity to mitral annular early diastolic velocity, body weight and glycaemic control after 12 weeks of treatment.


ETHICS AND DISSEMINATION
The study has been approved by the ethics committee and the patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals.


TRIAL REGISTRATION NUMBER
UMIN000018395.
['Ejiri|Kentaro|K|', 'Miyoshi|Toru|T|0000-0002-9039-3439', 'Nakamura|Kazufumi|K|', 'Sakuragi|Satoru|S|', 'Munemasa|Mitsuru|M|', 'Namba|Seiji|S|', 'Takaishi|Atsushi|A|', 'Ito|Hiroshi|H|']
D000368:Aged D003924:Diabetes Mellitus, Type 2 D005260:Female D065089:Glycoside Hydrolase Inhibitors D006333:Heart Failure D006801:Humans D007294:Inositol D008297:Male D008875:Middle Aged D020097:Natriuretic Peptide, Brain D011446:Prospective Studies D013012:Sorbitol D013318:Stroke Volume
luseogliflozin heart failure type 2 diabetes mellitus voglibose brain natriuretic peptide sodium-glucose cotransporter 2 inhibitor